The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Beyond steroids: Immunosuppressants in steroid-refractory/resistant immune related adverse events.
 
Jia Luo
No Relationships to Disclose
 
Jason Beattie
No Relationships to Disclose
 
Paige Fuentes
No Relationships to Disclose
 
Hira Rizvi
No Relationships to Disclose
 
Jacklynn V. Egger
No Relationships to Disclose
 
Jeffrey Kern
No Relationships to Disclose
 
Donald Y. M. Leung
No Relationships to Disclose
 
Mario E. Lacouture
Stock and Other Ownership Interests - OncoDerm (I)
Honoraria - ADC Therapeutics; Amgen; Apricity Health; AstraZeneca; azitra; azitra; Deciphera; Galderma; Genentech; Janssen; Johnson & Johnson; Kyowa Hakko Kirin; Loxo; Menlo Therapeutics; NCODA; Novartis; Novocure; OnQuality Pharmaceuticals; QED Therapeutics; Roche/Genentech; Seattle Genetics/Astellas; Teva; Teva
Consulting or Advisory Role - Abbvie; Adgero Biopharmaceuticals; Adjucare; Allergan; Amgen; Amryt Pharma; AstraZeneca; Bayer; Biotechspert; Boehringer Ingelheim; Celldex; Debiopharm Group; Dignitana; E.R. Squibb Sons, LLC; EMD Serono; Galderma; Genentech; Janssen Oncology; Janssen Research & Development; Johnson & Johnson; Legacy Healthcare Services; Legacy Healthcare Services; Lindi Skin; Lutris; Manner SAS; Menlo Therapeutics; Merck; Novartis; Novocure; OnQuality Pharmaceuticals; OurBrainBank; Parexel; Paxman; Pierre Fabre; QED Therapeutics; Roche; Roche; Roche; Roche; Seagen; Takeda/Millennium; Teva
Research Funding - Lutris; Novocure; Paxman; US Biotest; Veloce Pharmaceuticals
Travel, Accommodations, Expenses - AstraZeneca; Deciphera; Kyowa Hakko Kirin; Novocure; Teva
Other Relationship - OncoDerm (I)
(OPTIONAL) Uncompensated Relationships - OncoDerm; OncoDerm
 
Mark G. Kris
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Genentech/Roche; Novartis; Pfizer; Sanofi/Aventis
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Genentech; Pfizer
Other Relationship - Genentech/Roche; Memorial Sloan-Kettering Cancer Center
 
Maya Gambarin
No Relationships to Disclose
 
Bianca Santomasso
Consulting or Advisory Role - Celgene; Janssen; Legend Biotech
Research Funding - ADC Therapeutics (Inst)
 
David M. Faleck
Honoraria - TotalCME
Consulting or Advisory Role - Kaleido Biosciences
 
Matthew D. Hellmann
Stock and Other Ownership Interests - Arcus Biosciences; Immunai; Shattuck Labs; Shattuck Labs
Consulting or Advisory Role - Achilles Therapeutics; Arcus Biosciences; AstraZeneca/MedImmune; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Immunai; Merck; Mirati Therapeutics; Natera; Nektar; Shattuck Labs; Syndax
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - A patent has been filed by Memorial Sloan Kettering (PCT/US2015/062208) for the use of tumor mutation burden for prediction of immunotherapy efficacy, and which is licensed to Personal Genome Diagnostics. (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Lilly